ASH 2020 | Combining venetoclax with CPX-351 for AML
Tapan Kadia
• 3 Dec 2020
Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the findings of an investigation (NCT03629171) into combining CPX-351 and venetoclax to treat acute myeloid leukemia (AML). CPX-352 is a dual-drug made up of daunorubicin and cytarabine. The combination was tolerable and efficacy data is encouraging, particularly in the venetoclax-naïve subgroup. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
